On May 20, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform announced the formal registration of a Phase I clinical study. The study aims to evaluate the safety, tolerability, and pharmacokinetic profile of IBI3031 following…
On May 21, Eli Lilly announced positive results from the Phase III TRIUMPH-1 trial of Retatrutide, a GLP-1R/GIPR/GCGR agonist, for weight reduction. TRIUMPH-1 is an 80-week, randomized, double-blind, placebo-controlled Phase III trial (n=2339) evaluating the efficacy and safety of Retatrutide…
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will be held from May 29 to June 3 in Chicago, USA. Lepu Biopharma will present the latest data from its Phase 1/2 clinical trial of GPC3 ADC in advanced…
On June 2, the CDE official website announced that BMS’s Mezigdomide capsules have been formally included in the priority review process, which is expected to accelerate its approval and market launch in China. The drug is intended for the treatment…
Recently, the official website of the CDE (Center for Drug Evaluation, NMPA) indicates that Xiuqiu Zonggan Tablets and Xiuqiu Zonggan Extract, two Category 1.2 new TCM drugs co-developed by PROZIN PHARMACEUTICAL and the Institute of Materia Medica, Chinese Academy of…
On June 2, CSPC announces that the first mRNA-LNP-based bispecific chimeric antigen receptor (CAR)-T cell injection (SYS6063) developed by the company receives approval from China’s National Medical Products Administration (NMPA) to initiate clinical trials, indicated for relapsed/refractory systemic lupus erythematosus…
As a core driver target in solid tumors, EGFR is frequently activated in multiple cancer types, including colorectal cancer, lung cancer, and head and neck squamous cell carcinoma. However, EGFR also exhibits physiological expression in normal epithelial tissues, such as…
On May 25, Kelun-Biotech announced that in the global first Phase III OptiTROP-Lung05 study of a TROP2 ADC combined with immunotherapy as first-line treatment for patients with PD-L1 positive, driver gene-negative advanced non-small cell lung cancer (NSCLC), the median progression-free…
On May 27, 2026, Hengrui Pharma and Kailera Therapeutics, Inc. (Kailera) jointly announce positive topline results from the Phase 3 clinical trial (OUTSTAND-1) of the oral small-molecule GLP-1 receptor agonist HRS-7535 (known as KAI-7535 outside Greater China) in 284 adult…
May 26, 2026 – Henlius (2696.HK) announces that the first patient has been dosed in China in a randomized, double‑blind, multicenter, parallel‑controlled Phase II/III clinical study of the company’s self‑developed recombinant anti‑EGFR monoclonal antibody pimurutamab (HLX07) in combination with anti‑PD‑1…